Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,097 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Repeat Testing Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Effects of Alcohol After Bariatric Surgery

NCT01843257
View directory record Official record
Conditions
Obesity
Interventions
Alcohol challenge test Alcohol visit first, Alcohol challenge test Placebo visit first
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 30, 2026, 6:54 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude

NCT00724321
View directory record Official record
Conditions
Hypoxic Pulmonary Vasoconstriction
Interventions
iloprost
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 30, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04671667
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
178
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Withdrawn Not applicable Interventional

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

NCT00675532
View directory record Official record
Conditions
Drug Dependence
Interventions
Primary Care Counseling, Cognitive-behavioral psychotherapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Sensitization Test (Modified Draize-95 Test)

NCT03886987
View directory record Official record
Conditions
Skin Sensitisation
Interventions
Blue Non Sterile Powder Free Nitrile Examination Gloves
Device
Lead sponsor
Central Medicare Sdn. Bhd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 30, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers

NCT07413406
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Stress
Interventions
Structured Retrieval Practice, Reading-Based Education
Behavioral
Lead sponsor
Virginia Wesleyan University
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Assessment of Coronary Plaque Composition

NCT01581632
View directory record Official record
Conditions
Coronary Atherosclerosis, Endothelial Dysfunction, Coronary Small Vessel Disease
Interventions
LipiScan/LipiScan IVUS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 30, 2026, 6:54 AM EDT
Not yet recruiting Not applicable Interventional

Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors

NCT07250425
View directory record Official record
Conditions
Stroke, Neurological Diseases or Conditions, Hemiparesis;Poststroke/CVA, Gait Disorders, Neurologic, Post Stroke Fatigue, Motor Recovery, Walking Difficulty, Balance Impairment, Falls Prevention, Hemiparesis, Mobility Limitation
Interventions
Rise&Walk InHome by Healing Innovations
Device
Lead sponsor
Healing Innovations
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Prospective Validation of Prostate Biomarkers for Repeat Biopsy

NCT03082274
View directory record Official record
Conditions
Prostate Cancer
Interventions
ConfirmMDx, SelectMDx
Diagnostic Test
Lead sponsor
MDx Health
Industry
Eligibility
40 Years to 85 Years · Male only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Achilles Pain Block

NCT03316378
View directory record Official record
Conditions
Achilles Tendon Pain
Interventions
Ropivacaine injection
Drug
Lead sponsor
Ruth Chimenti
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 6:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction

NCT01974726
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
ET Stress test, Sonotubometry, Forced Response Test (FRT), Inflation Deflation Test (IDT), Maneuver Sequence, 9-Step Test, Tubomanometry, Videoendoscopic assessment of ETF, Pressure chamber ET test
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
3 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive, Refresh Optive MEGA-3
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225
View directory record Official record
Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
Procedure · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
409
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

NCT02877225
View directory record Official record
Conditions
Healthy
Interventions
Ibrutinib, IMBRUVICA
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fibersol-2 Clinical Trials Related to Appetite

NCT01305291
View directory record Official record
Conditions
Lack of Satiety
Interventions
placebo, digestion-resistant maltodextrin
Other · Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Feasibility of HIIT in Spinal Cord Injury

NCT03152110
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Diseases
Interventions
HIIT
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Diabetes-Depression Care-management Adoption Trial

NCT01781013
View directory record Official record
Conditions
Depression, Diabetes Mellitus
Interventions
Technology-supported care
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
El Monte, California • Lancaster, California • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Enhancing Adolescent Substance Abuse Treatment

NCT03249350
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Standard Contingency Management (CM), Enhanced Contingency Management (CM+)
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
12 Years to 18 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

NCT07632768
View directory record Official record
Conditions
Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions
Discontinuation of Pancreatic Enzyme Replacement Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
0 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

NCT03284385
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Adavosertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Orange, California • Sacramento, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

NCT04439318
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

NCT05063552
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 6:54 AM EDT